This is a single group, Phase 2, long-term extension study for treatment. The purpose of this
study is to characterize the safety and efficacy of amlitelimab in treated adult participants
with moderate to severe AD who have previously been enrolled in study KY1005-CT05 (DRI17366).
Visits during the on-treatment period will be at Week 0, 1, 2, 4 and every 4 weeks (Q4W)
thereafter. If remote or telephone visits are considered appropriate for participants instead
of clinic visits at the timepoints indicated in the schedule of activities (SoA), home visits
(e.g., home nurses, etc) will be required for administration of investigational medicinal
product (IMP) and assessment of vital signs. This decision is at the discretion of the
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.